MBX Biosciences, Inc. (MBX)
66.31
-0.45
(-0.67%)
USD |
NASDAQ |
Aug 27, 13:03
MBX Biosciences Net Income (Quarterly) : -37.10M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -37.10M |
| March 31, 2026 | -23.52M |
| December 31, 2025 | -22.06M |
| September 30, 2025 | -21.62M |
| June 30, 2025 | -19.41M |
| March 31, 2025 | -23.88M |
| December 31, 2024 | -15.59M |
| Date | Value |
|---|---|
| September 30, 2024 | -18.14M |
| June 30, 2024 | -15.86M |
| March 31, 2024 | -12.34M |
| December 31, 2023 | -8.843M |
| September 30, 2023 | -10.16M |
| June 30, 2023 | -7.608M |
| March 31, 2023 | -5.949M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Amylyx Pharmaceuticals, Inc. | -43.42M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 37.10M |
| EPS Diluted (Quarterly) | -0.7777 |
| Enterprise Value | 2.786B |
| Earnings Yield | -3.63% |
| Normalized Earnings Yield | -3.629 |